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Liability for Post-Transfusion AIDS:
An Analysis and Proposal*
*In the time between writing and publication,
specific numbers quoted in this Note may have
been superceded, but the trends in the course
of AIDS and blood-transfusion law have not
substantially changed. The Editor
I. Introduction
The nature of the acquired immune deficiency syndrome (AIDS) epi-
demic and the methods used to protect the blood supply from contamina-
tion by the AIDS virus indicate that an increasing number of actions seeking
recovery for post-transfusion infection may reach the courts in the next dec-
ade. The theories under which plaintiffs usually seek relief for transfusion-
related infection - e.g., negligence or strict liability - lead to complex fac-
tual, procedural, and public policy problems which do not readily lend
themselves to consistent, just adjudication.
The interests of fairness, judicial efficiency, and preservation of an ade-
quate and safe blood supply may be best served by codification of certain
surgical and blood-collection practices already being observed in many
areas. Codification of these practices will serve to supply a uniform standard
of care for both the judiciary and the medical/blood-service community. It
will also put the public on notice of a risk that they may not have foreseen
and serve to ensure the safety of the blood supply.
Details of blood collection and testing are key to this discussion. They are
therefore described at some length in this Note. The theories under which
plaintiffs may seek recovery for transfusion-related illness or death are ex-
amined in light of what is known of the AIDS virus and current medical prac-
tices. Finally, legislative proposals will be suggested which may alleviate
many of the problems related to the nature and scope of the possibility of
AIDS in the blood supply.
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II. The Nature of AIDS
Acquired Immune Deficiency Syndrome (AIDS) is a severe suppression
of the immune system, characterized by a range of opportunistic infections
(i.e., caused by microorganisms that rarely cause infection in healthy indi-
viduals) and uncommon cancers,' or disturbing nervous system disorders.2
Nearly 22,000 victims of AIDS have been identified to date (mid-1986), all of
whom will probably die in the next few years. 3 The average life expectancy of
AIDS victims is eighteen to twenty-four months, but some individuals have
survived up to six years.4 At present, it is invariably fatal.5
AIDS was first recognized in the United States in 1979, but retrospective
examinations of blood samples from Zaire show positive serological re-
sponses to human immunodeficiency virus as far back as 1959 6 Human im-
munodeficiency virus (HW) has been isolated from blood, semen, saliva, tears,
breast milk and urine. 7 The virus has been shown to be spread by sexual in-
tercourse with an infected male or female partner, by introduction of in-
'Ammann, What We Can Say About Acquired Immune Deficiency Syndrome, CONSULTANT, Sept.
1983, at 35.
2Angerer, Angerer, Berin & Eskins, Human T-Cell Lymphotropic Virus Type III Infections of the
Central Nervous System, 256 J.A.M.A. 2360 (1986).
3Seligmann, Hager & Springen, Spreading Alarm About AIDS, NEWSWEEK, June 23, 1986, at 68
[hereinafter Seligmann].
'McLaughlin, AIDS Update, CLEvELAND BAR ASSOCIATION HEALTH CARE LAW INSTITUTE, at 1
(April 15, 1986) (available in JOURNAL of LAW and HEALTH offices).
5Langone, AIDS Update: Still No Reason for Hysteria, DISCOVER, Sept. 1986, at 28.
The Centers for Disease Control (CDC) estimate that between 1.0 and 1.5 million Americans
have already been infected with the virus responsible for the spread of AIDS, human immuno-
deficiency virus (1-11V), Baum, AIDS Researchers Make Inroads in Understanding a Complex Virus, 64
CHEM CAL& ENGNERING NEws 7 (1986). (Throughout this Note, the putative agent responsible
for the spread of AIDS will be referred to as human immunodeficiency virus, or HIV. In the
literature, it is variously referred to as human T-cell leukemia virus-Ill, or HTLV-III,
lymphadenopathy-associated virus, or LAV; HTLV-IfILAV or LAV/HTLV-Ill. These all refer to
the same putative agent.) 20% to 30% of those infected will actually develop AIDS per se.
Langone, at 29. Others infected may develop AIDS-related complex (ARC), characterized by
swollen lymph nodes, fever, diarrhea or other symptoms, while up to 50% of those infected
may show no symptoms at all. Baum, 9. Fifteen to twenty percent of individuals diagnosed with
ARC convert to AIDS in a two to five year period. McLaughlin, supra note 4, at 2. In some cases,
no symptoms are manifested for up to eight years. Office of Medical Applications of Research,
National Institutes of Health, The Impact of Routine HTL V-III Antibody Testing of Blood and Plasma
Donors on Public Health, 256 J.A.M.A. 1778, 1780 (1986).
6Quinn, Mann, Curran & Piot, AIDS in Africa: An Epidemiologic Pardigm, 234 SCIENCE 955, 956
(1986) [hereinafter Quinn].
7McLaughlin, supra note 4, at 3.
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fected blood or blood products into the bloodstream, or in utero infection of
fetuses by HIV-carrying mothers.'
Approximately 72.5% of AIDS victims are homosexual or bisexual men,
16.8% are intravenous drug users, and 1.4% are children. 9 Hemophiliacs
and transfusion recipients make up approximately 0.8 and 1.7% respec-
tively.10 These relative proportions have remained remarkably constant over
time." By 1991, the Department of Health and Human Services anticipates
that 270,000 Americans may be diagnosed as having AIDS. 2
Efforts to combat the spread of AIDS center primarily on educating high
risk groups and the general population on how the virus is transmitted 3 be-
cause the development of a vaccine for AIDS is unlikely for a minimum of
five years. 4
Once an individual has been infected with HIV the virus will persist in-
definitely, and that individual will be at risk of developing AIDS, AIDS-
related complex (ARC), or becoming an avenue of infection to others."1 Most
of the spread of HIV to persons not already infected may be eliminated by
the use of "safe sex" methods (e.g., monogamy, use of condoms) or by the
avoidance of shared intravenous (IV) drug needles.'6 By eschewing high-risk
practices, an individual can radically reduce his chance of HIV infection by
the predominant characterized vectors. 7
Notwithstanding the above, the HIV factor is predicted to be present in 5
to 10,000,000 Americans by 1991.18 The largest part of this continued spread
will probably be due to lapses in public awareness or misunderstanding of
'Baum, supra note 5, at 8.
Norman, Sex and Needles, Not Insects and Pigs, Spread AIDS in Florida Town, 234 SCIENCE 415,
416(1986).
"Id.
"Op. ATry GEN., No. 86-19, slip op. at I (Ga. April 24, 1986).
"2Seligmann, supra note 3.
"Norman, $2-Billion Program Urged for AIDS, 234 SCIENCE 661 (1986).
'
4War on AIDS: Panel Urges More Education, Research, 64 CHEMICAL & ENGINEERiNC NEWs 4
(1986).
"5Morganthau, Hager, Cohn, Raine, Reese, Anderson & Ernsberger, Future Shock,
NEwswEEK, Nov. 30, 1986, at 30, 31 [hereinafter Morganthaul.
1C. Koop, SURGEON GENERAL'S REPORT on ACQUIRED IMMUNE DEFICIENCY SYNDROME (1986).
'
7Address by Dr. Mervin Silverman, Pres. of American Foundation for AIDS Research,
Cleveland City Forum (Jan. 30, 1987).
"Morganthau, supra note 15, at 31.
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the nature of the disease.19 An important part of the spread, however, which
will not be restricted to high risk groups, will be through unwitting transfu-
sion of HIV-contaminated blood. '
III. Disease and the Blood Supply
AIDS is not the only disease which may be spread via blood transfusion.
Hepatitis, cytomegalovirus, and malaria are other serious diseases that may
be so transmitted.2 In the case of hepatitis, 0.02 to 25% of the patients receiv-
ing conventional homologous 2 transfusions develop post-transfusion hepa-
titis, though the largest part is subclinical or asymptomatic. 2
Recognizing the possibility that diseases may be so transmitted, blood
banks follow several standard procedures designed to minimize risk. Blood
donors are usually interviewed about their general health, well-being, and
medical history to prescreen inappropriate donors. 24 After the blood is
drawn into a plastic bag, tests for ABO blood type, syphilis, hepatitis B sur-
face antigen, and the HIV antibody are then performed on the blood. These
tests are usually performed regardless of the answers to the pre-donation
interview. 2The blood may then be stored until ordered for transfusion for
up to 45 days in a refrigerator, depending on the anticoagulant preservative
solution.2 Alternatively, it may be separated into red cells, clotting concen-
trate, and plasma ("components"), the latter of which may be further pro-
"For example, a survey of San Francisco high school students showed that 40% were un-
aware that use of a condom during intercourse decreases risk of infection. Norman, supra note
13.
2"Heil & Hemley, Taking Aim at AIDS, HIGH TECHNOLOGY, Jan. 1987, at 44.
"Council on Scientific Affairs, American Medical Association, Autologous Blood Transfusions,
256 J.A.M.A. 2378 (1986).
12Homologous blood transfusions use conventionally-collected, essentially random third-party
blood donations. Autologous blood donations use blood previously donated by the patient for use
during his operation. Directed donations are from specific donors - usually family or friends -
for a specific patient.
'Coffin, Current Issues in Transfusion Therapy, POSTGRADUATE MEDICINE, Dec. 1986, at 219,
220. Estimates vary depending on differences in definition and methods of detection,
"See, e.g., Hoder v. Sayet, 196 So. 2d 205 (Fla. Dist. Ct. App. 1967).
"5Cooper, Blood: Its Components and Derivatives, LEGAL ISSUES IN TRANSFUSION MEDICINE 15, 16
(1985).
"6See, e.g., Morse v. Riverside Hosp., 44 Ohio App. 2d 442, 339 N.E.2d 846 (1974).
17Cooper, supra note 25, at 16.
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cessed into such products as albumin or serum globulins ("derivatives").3
This separation process may lead to the pooling of plasma from thousands of
donors.2 9
Pre-screening of donors and testing for antigens does not, however, elim-
inate the risk of infection. Blood products may have warnings to that effect. 3
In the case of AIDS, high risk populations have been identified, as have
high risk behaviors. In addition, FDA-approved diagnostic tests are com-
mercially available for routine screening of blood for indications of HIV pres-
ence. 31 The human immunodeficiency virus causes the infected person's im-
mune system to produce specific HIV antibodies which may be detected by
the most commonly used test, Enzyme-Linked Immunosorbent Assay, or
ELISA.31 A second, more specific type of test, the Western Blot assay, is used
by the non-profit blood banking system to provide unambiguous identifica-
tion of infected donors.3
It has been suggested in the medical literature that an initial negative
ELISA result being accepted as proof of absence of HIV antibodies may be a
flaw in the testing protocol, allowing the use of otherwise excludable (i.e.,
contaminated) blood samples.3 Further, because the commercial ELISA di-
agnostic tests detect only HIV antibodies (and not HIV itself), and the body
may take from three to six months after exposure to the virus to produce
sufficient antibodies to be detected, any blood donation in that interim pe-
jId. at 15.
111d. at 21.
3'See, e.g., Fogo v. Cutter Laboratories, 68 Cal App. 3d 744, 137 Cal. Rptr. 417 (1977).
31Heil & Hemley, supra note 20, at 45.
3Office of Medical Applications of Research, supra note 5, at 1779. Because of its high sensi-
tivity, if one ELISA test indicates that HIV antibodies are present (i.e., tests positive), two moe
ELISA tests are performed: if both subsequent tests are negative, the blood is considered accept-
able; if either test is positive, the blood is destroyed. Id. Each ELISA test costs approximately $6.
Morganthau, supra note 15, at 39. Repeat testing reduces the potential for "false positives"
which would cause needless destruction of possibly safe blood and disqualification of a donor
for future blood donations. Safeguarding America's Blood Supply, DuPoN, MArzAziz , Jan.-Feb.
1987, at 22, 23.
-1If a donor shows repeat positive ELISA reactions, and shows a positive Western Blot test,
the individual is considered infected. Office of Medical Applications of Research, supra note 5,
at 1779. If the Western Blot is negative, the individual is probably not infected, but the specific
blood sample is disposed of, regardless. Id. The Western Blot test is considered impractical for
mass screenings. Safeguarding America's Blood Supply, supra note 32, at 23. It requires special
equipment, expertise, and is difficult to standardize. Office of Medical Applications of Re-
search, supra note 5, at 1779. Each Western Blot test costs $60 to $80. McLaughlin, supra note 4, at
2.
'Mann, Screening Blood Donors for HTLV-IIAntibody, 256 J.A.M.A. 2344 (1986). For details of
ELISA protocol, see note 32.
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riod will not be rejected as tainted. False negatives therefore cannot be
eliminated from either the ELISA or Western Blot tests, because some serum
samples will contain too little antibody to be detected due to too short time
between exposure and donation or slow formation of antibodies 3 6 Newly
developed tests which detect the presence of the virus directly may amelio-
rate these problems when commercially available, 37 assuming they receive
FDA approval and are suitable for large-scale, routine use.
Between 12 million and 23 million units of blood are collected each year.
Approximately $60 million was spent on blood-bank screening in the United
States in 1985 alone,10 and the market for AIDS diagnostics is expected to
reach $400 million worldwide by 1990. 41 Each unit of blood or blood compo-
nent carries with it a number identifying the donor 2 In the event a donor
tests positive for HIV-antibodies, recipients may be tracked down for subse-
quent HlV-testing to be warned, counseled, etc. Programs of this nature are
already in place in New York, San Francisco, and elsewhere.4
Given the HIV-antibody test limitations, however, detection may not oc-
cur and each recipient may thereby become another vector for spreading
HIV. The same holds true for donors who have had sexual relations with an
WV-carrying partner in the last six months - whether the partner was het-
erosexual, homosexual, bisexual, a prostitute, or in any other way non-
monogamous which allowed exposure to HIV.
Because of the sheer number and diversity of such encounters, and the
potential for non-detection up to six months after exposure, it is likely that
the next few years will see an increasing amount of litigation arising over the
question of blood supplier liability for AIDS infection via blood transfusion.
3Heil & Hemley, supra note 20, at 46.
'Office of Medical Applications of Research, supra note 5, at 1779.
370ncor to Offer Test to Detect AIDS Virus, 64 CHEMICAL & ENGEERiNG NEws 6 (1986).
'Clark, AIDS: The Trail of Tainted Blood, NEwswEEK, Aug. 25, 1986, at 55.
"Heil & Hemley, supra note 20, at 45.
eQuinn, supra note 6, at 962.
41Heil & Hemley, supra note 20, at 44.
'Clark, supra note 38.
4Id. Between May, 1985, and August, 1986, the Look Back Program in San Francisco traced
about 400 recipients of HIV-antibody-positive blood, seven of whom had developed AIDS.
[Vol. 2:215
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IV. Approaches to Recovery
Blood products manifest many of the elements associated with the con-
cept of "product" - packaging of discrete units with intrinsic economic
value for introduction into commerce." The transactions related to blood
transfusion - a bargained-for exchange of a property (blood) for a consider-
ation (money) - appear to have the major attributes of a sale." It seems rea-
sonable, then, that transfusion of blood or its components may, in some con-
texts, be considered a sale of a product for contract or tort liability purposes.
If they were considered products in the usual sense, blood and blood prod-
ucts would be subject to such statutory provisions as the Uniform Commer-
cial Code implied warranties of merchantability and fitness for a particular
purpose." If a patient could show that he had contracted an illness from a
blood transfusion, then the blood transfused is certainly unfit for its obvious
intended use, and the patient could pursue recovery based on breach of im-
plied warranties. A significant part of the case law surrounding blood trans-
fusion, in which recovery is typically sought for transmission of hepatitis,
follows this thinking."
In Mercy Hospital, Inc. v. Benitez, for example, a patient tecovered against a
hospital-operated blood bank after contracting hepatitis.*4 The court held
that the transaction regarding the blood, involving transfer of a product for a
consideration, constituted a product sale (governed by contract law), and
not a service (governed by the law of torts), thus allowing an action for
breach of warranty."1 Rostocki v. Southwest Florida Blood Bank, Inc.,5° relying on
the reasoning of Mercy Hospital, extended this strict liability based on con-
tract theories to blood banks outside the hospital, which are unambiguously
concerned with sales of blood rather than rendering medical services. The
"Though many blood banks are themselves non-profit organizations, hospitals may charge
patients up to $250 per unit used. Cooper, supra note 25, at 18. Questions of charitable or gov-
ernmental immunity will not be discussed in this Note.
4"See, e.g., Reilly v. King County Cent. Blood Bank, 6 Wash. App. 172, 492 P.2d 246 (1971).
"See, e.g., U.C.C. § 2-314 (implied warranty of merchantability), § 2-315 (fitness for particu-
lar purpose), § 2-318 (extension to certain third parties). But see U.C.C. § 2-607 (requirement that
buyer must notify seller of breach within a reasonable time or be barred from remedy).
'See, e.g., Belle Bonfil Mem. Blood Bank v. Hansen, 195 Colo. 529, 579 P.2d 1158 (1978)
(blood bank clearly selling blood; hospital providing services); Mercy Hosp. v. Benitez, 257 So.
2d 51, (Fla. Dist. Ct. App. 1972) (blood from hospital blood bank is a product to which warran-
ties of fitness apply); Reilly v. King County Cent. Blood Bank, 6 Wash. App. 172, 492 P.2d 246
(1971).
48Mercy Hosp., 257 So. 2d at 51.
49ld.
SORostocki v. Southwest Fla. Blood Bank, 276 So. 2d 475 (1973).
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Rostocki court held that since blood is intended for human consumption, the
provider thereof should be held strictly liable for harms resulting from de-
fects therein, just as are vaccine or food product manufacturers.51
Earlier decisions held under similar circumstances that to hold manufac-
turers of products intended for human consumption liable for harms they
cause only if the deleterious substance was capable of being detected or re-
moved would be counter to fundamental strict liability theory: "[A] manu-
facturer's or seller's actual knowledge or opportunity for knowledge of a de-
fective or unwholesome condition is wholly irrelevant to his liability on the
theory of implied warranty .. ."52
However, the implied warranty theory is generally applicable only to
sales, and not to services, and all but four states currently have statutes de-
fining blood supply as a service or excluding blood from its definition of a
product. Even without statutory preclusion, however, many courts had re-
jected implied warranty suits for post-transfusion illness on the basis of the
sales/service distinction alone. In Perlmutter v. Beth David Hospital, M the New
York Court of Appeals reasoned that although certain tangible goods -
medicine, blood - were provided for a patient, the contract between patient





2Community Blood Bank v. Russell, 196 So. 2d 115, 119 (Fla. 1967) (Roberts, J., concurring
specially).
53ALA. CODE § 2-314 (1985); ALASKA STAT. § 45.02.316 (1985); ARi. REV. STAT. ANN. § 32-1481,
36-1151 (1985); ARK. STAT. ANN. §§ 82-1608, 85-2.316(3)(d) (1985); CAL. HEALTH & SAFETY CODE §
1606 (West 1984); COLO. REV. STAT. § 41-2-11 (1985); CONN. GEN. STAT. § 139-1 (1984); FLA. STAT. §
672-316(5) (1985); GA. CODE ANN. §§ 11-2-316, 51-1-28 (1984); HAW. REV. STAT. § 327.15 (1984);
IDAHO CODE §§ 6-1402(3), 39-3702 (9184); ILL. REV. STAr. ch. 111, § 5102 (1985); IND. CODE § 16-8-
7.2 (1984); IOWA CODE § 142A.8 (1985); KAN. STAT. ANN. § 65-37d (1985); KY. REV. STAT. § 139.125
(Baldwin 1984); LA. CIV. CODE ANN. art. 1764 (Act No. 301 West 1968); ME. REV. STAT. ANN., tit.
11, § 2-108 (1983); MD. HEALTH-GENERAL CODE ANN. § 18-402 (1985); MASS. GEN. LAWS ANN. ch.
106, § 2-316(5) (West 1984); MicH. CoMP. LAWS § 691-1511 (1985); MINN. STAT. § 525-928 (1983);
Miss. CODE ANN. § 41-41-11 (1985); Mo. REv. STAT. § 431.069 (1985); MONT. CODE ANN. § 50-33-102
(1985); NEB. REv. STAT. § 71-4001 (1985); NEV. REv. STAT. § 460.010 (1984); N.H. REV. STAT. ANN. §
507.8b (1985); N.M. STAT. ANN. § 24-10-5 (1985); N.Y. PuB. HEALTH LAW § 580.4 (McKinney 1985);
N.C. GEN. STAT. § 90-220.10 (1984); N.D. CENT. CODE § 41.02-33(3)(d) (1985); Omo REV. CODE
ANN. § 2108.11 (Baldwin 1985); OKLA. STAT. tit. 63, § 34-2151 (1984); OR. REV. STAT. § 97.300
(1985); PA. STAT. ANN. tit. 35, § 10021 (Purden 1985); S.C. CODE ANN. § 44-43-10 (Law Co-op
1984); S.D. CODIFIEDANN. LAWS § 57A-2-315.1 (1985); TENN. CODE ANN. § 47-2-316(5) (1984); TEx.
Bus. & COM CODE ANN. § 2-316(e) (Vernon 1985); UTAH CODE ANN. § 26-31-1 (1984); VA. CODE §
32.1-297 (1984); WASH. REV. CODE ANN. § 70.54.120 (1985); W. VA. CODE § 16-23-1 (1984); Wis.
STAT. § 146.31 (1984); Wyo. STAT. § 34-21-233, 35-221-10 (1985).
5'Perlmutter v. Beth David Hosp., 308 N.Y. 100, 123 N.E.2d 792 (1954).
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It has been held, however, that even though the transaction could not be
characterized as a sale, a patient could nonetheless recover on an implied
warranty theory.0 Further, in what has become a key case in blood transfu-
sion law, Brody v. Overlook Hospital it has been held that, "If it is otherwise
determined that the basic policy considerations which lead to the applica-
tion of the doctrine of strict liability are here present, that doctrine will be
applied regardless of whether such activity... be characterized as a sale or a
service." In this case, plaintiff has developed serum hepatitis and died after
receiving a blood transfusion.
In what has become known as the strict liability in tort doctrine, articula-
ted in Restatement, Second, Torts, § 402A,' 1 the seller of a defective, unrea-
sonably dangerous product is liable for physical harms to users or con-
sumers if it reaches those users or consumers without substantial change in
the condition in which it was sold, notwithstanding that the seller exercised
all possible care in preparation and sale of that product. s7 In that no negli-
gence needs to be proved, strict liability provides an effective incentive to
offer the safest products possible for market consumption.
Imposition of strict liability on blood suppliers not immune from suit
would make their business more financially risky, given that the estimated
costs involved with the care of an individual contracting AIDS may be
$50,000 per patient per year. 8 This could easily lead commercial blood sup-
pliers to choose to leave the blood supply business, perhaps further exacer-
bating the severe blood shortages felt in numerous metropolitan areas. 9
Notwithstanding the above, blood and blood products are typically sup-
plied in packages which are to be used as delivered, without any modifica-
tion by the physician or other party. Also, transfusion procedures other than
1"Hoffman v. Misericordia Hosp. of Philadelphia, 439 Pa. 501, 267 A.2d 867 (1970) (even if
not technically a sale, recovery based on breach of warranty allowed).
5Brody v. Overlook Hosp., 127 N.J. Super. 331, 317 A.2d 392 (1974), affd, 66 N.J. 448, 332
A.2d 596 (1975). Uncontroverted evidence adduced at trial indicated that the overall incidence
of transfusion hepatitis was "about 1.3 in a hundred cases transfused," Brody, 66 N.J. at 449, 332
A.2d at 597. a considerably higher incidence than the chance of contracting AIDS from blood,
which is estimated to be one in 250,000. Clark, supra note 38. Estimates of blood contamination
by HIV run as high as 1 in 500, based on a U.S. Public Health Service assessment that HIV-
antibody testing is 99.8% reliable. S.F. Chronicle, Aug. 1, 1985, at 6, col. 1.
17Restatement (Second) of Torts § 402A (1965). "The purpose of such liability is to insure that
costs of injuries resulting from defective products are borne by the manufacturers that put such
products on the market rather than the injured persons who are powerless to protect them-
selves." Greenman v. Yuba Power Products, 59 Cal. 2d 57, 377 P.2d 897, 27 Cal. Rptr. 697 (1963).
m'Morganthau, supra note 15, at 33. Location, type of care, and other factors result in large
variations in the cost of care.
"Safeguarding America's Blood Supply, supra note 32, at 22.
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combining blood products are unlikely to produce HIV contamination in a
given unit.60 In addition, HIV- or hepatitis-contaminated blood is inarguably
defective. It is thus no surprise that blood has been held to be a product
within the ambit of § 402A. 61 Further, relying on the language of § 402A, Cun-
ningham v. MacNeal Memorial Hospitall maintained that inability to detect
hepatitis in blood was irrelevant to a strict liability discussion.
Like the Brody court, the Cunningham court examined the language of
§ 402A, focussing especially on the "unreasonably dangerous" criterion.
The Brody court had found that as "a prerequisite to the application of the
doctrine of strict liability a plaintiff must show that the product he alleges as
defective was unreasonably dangerous for its intended use."63 Brody went on
to dassify blood as an "unavoidably unsafe product" as defined by Com-
ment k of § 402A, and thus not unreasonably dangerous." Comment k pro-
vides:
Unavoidably unsafe products. There are some products which,
in the present state of human knowledge, are quite incapable of be-
ing made safe for their intended and ordinary use. These are espe-
cially common in the field of drugs. An outstanding example is the
vaccine for the Pasteur treatment of rabies, which not uncommonly
leads to very serious and damaging consequences when it is in-
jected. Since the disease itself invariably leads to a dreadful death,
both the marketing and the use of the vaccine are fully justified, not-
withstanding the unavoidable high degree of risk which they in-
volve. Such a product, properly prepared, and accompanied by
proper directions and warning, is not defective, nor is it unreason-
ably dangerous. The same is true of many other drugs, vaccines,
and the like, many of which for this very reason cannot legally be
sold except to physicians, or under the prescription of a physi-
cian .... The seller of such products, again with the qualification
that they are properly prepared and marketed, and proper warning
'If sometimes they take the unit of blood and decide, "Well, I have to give an antibiotic at the
same time, I'm just going to squirt the antibiotic into the unit of blood," you can get an allergic
reaction or hemolysis. We try to convince doctors to leave blood alone and not doctor it up with
other stuff." Ness, What Can Go Wrong With Transfusion, LEcAL ISSUES IN TRANsFusIoN MEDICINE
25, 30 (1985).
"Cunningham v. MacNeal Mem. Hosp., 47111. 2d 443, 266 N.E.2d 897 (1970).
621d. at 443, 266 N.E.2d at 903. For a detailed analysis of Cunningham, see 69 MIcH. L. REv.
1172 (1971).
'Brody, 332 A.2d at 394 (italics in original).
"Brody, 332 A.2d at 394.
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is given, where the situation calls for it, is not to be held to strict lia-
bility for the unfortunate consequences attending their use, merely
because he has undertaken to supply the public with an apparently
useful and desirable product, attended with a known but appar-
ently reasonable risk.6
Cunningham, narrowly construing Comment k as applying only to "prod-
ucts which are not impure,"" imposed strict liability against the defendant
hospital because hepatitis-infected blood is obviously impure. The Cun-
ningham holding has been criticized for its narrow construction,7 and its rea-
soning was explicitly rejected by the Brody court."
As previously discussed, the current state-of-the-art large-scale HIV test-
ing is the ELISA HIV-antibody detection method. This method cannot de-
tect contamination of a blood sample unless enough time has passed since
infection for sufficient antibodies to have been produced to be detected.
Developmental tests which detect the HIV itself are not commercially availa-
ble or FDA approved at this writing and may not be suitable for large-scale
testing. Moreover, 3% of known AIDS victims have no known risk factors, 9
and therefore could not have been discovered by any pre-screening inter-
view or examination. Heterosexual transmission is predicted to account for
9% of AIDS cases in the U.S. by 1991.'1 The incubation period between infec-
tion by the virus and the onset of AIDS or ARC symptoms may be as long as
eight years. The identifiable high-risk behaviors pre-screening interviews
are intended to discover, therefore, will become more and more common-
place, because the chances that a given potential donor has unwittingly con-
tacted HIV in the previous few weeks from an asymptomatic (though possi-
bly clinically detectable) individual will have become much higher.
According to the Red Cross, the list of individuals who should refrain
from donating blood or plasma already include any man who has had sex
with a man since 1977; persons of either sex who have taken illegal drugs
intravenously; natives of Burundi, Kenya, Rwanda, Tanzania, Uganda, or
Zaire who entered the U.S. after 1977; hemophiliacs that have received clot-
ting factor concentrates; persons who have tested positive for the HIV anti-
65Restatement (Second) of Torts § 402A (1965), Comment k.
"Cunningham, 47 Il. 2d at 444, 266 N.E.2d at 904.
"See 69 Mic-i. L. REV. 1172 (1971); 24 VAND. L. Ray. 645 (1971); 16 VILL. L. REV. 983 (1971); 66
NW. U.L. Rav. 80 (1971); 32 Omo ST.L.J. 585 (1971).
"Brody, 332 A.2d at 395.
"Norman, supra note 9, at 416.
7WMorganthau, supra note 15, at 31.
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body; persons with AIDS or its symptoms; male or female prostitutes; the
sex partners of any of the above-described individuals since 1977. 7 Realisti-
cally, then, blood products cannot be supplied without a finite chance that
they are HIV-infected, and therefore cannot be supplied entirely "safe for
their intended and ordinary use." This chance is estimated by the Surgeon
General to be less than one in 100,0007 which translates into between 120
and 230 contaminated units annually in the U.S."
According to Comment k, the justification for the use of blood products
that are accompanied by a risk of carrying HIV must be a function of their
"useful and desirable product nature." The risk of deleterious effects must
therefore be weighed against the therapeutic value of blood products and
the availability of alternative, lower-risk treatments. In treatment of trauma
cases involving substantial loss of blood, for example, the risk of AIDS may
be dearly outweighed by the risk of imminent death.
In other cases, for example hemophilia, the balance is not between one
present risk and another, but between the risk of HIV exposure and the
value of a more normal lifestyle, aided by blood coagulants isolated from
many separate donors. The plasma of 1,000 to 20,000 donors is pooled to
produce a given lot of factor concentrate, and the approximate factor usage
in a year by a hemophiliac may range from less than 15,000 to more than
60,000 units. 7 The risk is therefore very high for hemophiliacs, and in fact
the prevalence of HV antibody in hemophiliacs exceeds 90%.75 Techniques
have been developed to heat-treat coagulation concentrates that eliminate
most of the risk of transmission. 76 This advance in the Comment k "proper
preparation" requirement for these particular products may be relevant to
hemophiliac treatment begun since the development of this procedure,
since the average adult with hemophilia receives 40 to 60 transfusions per
year.77
7tGabe, Keeping the "Gift of Life" Ever-flowing, The Plain Dealer (Cleveland), Feb. 24, 1987, at 7-
B, col. 6.
72Koop, supra note 16, at 22. But see supra note 56 and accompanying text.
'This is determined by multiplying the total units of blood collected by the fraction of blood
contaminated. Based on twelve to twenty-three million units (see supra notes 38 and 39 and ac-
companying text) and 1/500 contamination rate (see supra note 56), HIV contamination could run
as high as twenty-four to forty-six thousand units.
7'The Hemophilia/AlDS Collaborative Study Group, Effect of Exposure to Factor Concentrates
Containing Donations from Identified AIDS Patients, 256 J.A.M.A. 1758, 1759 (1986).
"Bennett, AIDS Epidemiology Update, 85 AM. J. NURSING 968, 970 (1985).
76Cooper, supra note 25, at 22.
"Bennett, supra note 75, at 970.
[Vol. 2:215
LIABILITY FOR POST TRANSFUSION AIDS
In the case of major surgical operations, often several units of blood are
transfused to maintain homeostasis, each unit attended by its own risk. The
possibility of contracting AIDS must then be weighed against the utility of
the surgery. In the case of necessary surgery, the case is not fundamentally
different from an emergency situation, other than that the consent of the pa-
tient may be sought. In the case of elective surgery, however, it is again a
balancing of the risk of HIV exposure against the quality of life without the
procedure.
To summarize briefly, the plaintiff seeking to recover under a strict liabil-
ity theory may find that a breach of warranty approach can fail because
blood supply can be characterized, often by statute, as a service to which
UCC theories are inapplicable. Pursuing a strict liability in tort approach, he
may find that approach blocked by characterization of blood and blood
products as "unavoidably unsafe." Further, there is a reasonable chance that
a national Product Liability Act may pass into law in the relatively near fu-
ture, precluding state statutes and case law in that area.78 These proposed
laws, as well as the proposed Model Uniform Product Liability Act, uni-
formly exclude blood and its constituents from their coverage,7 and,
thereby, exclude blood from most applications of the strict liability doctrine.
A res ipsa loquitor theory may likewise prove unsuccessful, given the epi-
demiology of AIDS. Unlike unexplained injuries to an unconscious patient, °
it is statistically unlikely that transfusion, rather than one of the other epide-
miologically identified vectors, caused a given case of AIDS. 8'
There are more conventional negligence theories, however, which do not
have the statutory, doctrinal, or demographic roadblocks to which the the-
ories discussed so far are prone. However, conventional negligence theories
require proof of the elements of the tort (duty of care, breach of that duty,
harm, proximate cause) that the other theories dispense with. These prob-
lems of proof can be particularly difficult to overcome.
One avenue of negligence liability would be the physician's failure to
warn the patient of the risk of HIV infection through transfusion. This in-
formed consent action, a subclass of medical malpractice, may lie if:
'8U.S. CONST. art. VI, § 2.
'
9See, e.g., MODEL UNIFORM PRoDuCT LIABIrny Acr § 102(c); S.100, 99th Cong., 1st Sess.
§ 2(11).
a'Ybarra v. Spangard, 93 Cal. App. 2d 43, 208 P.2d 445 (1949).
"See supra notes 9 and 10 and accompanying text.
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(1) defendant physician failed to inform him (the patient) ade-
quately of a material risk before securing his consent to the proposed
treatment;
(2) if he (the patient) had been informed of the risks he would not
have consented to the treatment;
(3) the adverse consequences that were not made known did in
fact occur and he (the patient) was injured as a result of submitting
to the treatment.w
Courts have been particularly emphatic about this aspect of physician duty:
A medical doctor, being the expert, appreciates the risks inherent in
the procedure he is prescribing, the risks of a decision not to un-
dergo the treatment, and the probability of a successful outcome of
the treatment. But once this information has been disclosed, that as-
pect of the doctor's expert function has been performed. The weigh-
ing of these risks against the individual subjective fears and hopes of
the patient is not an expert skill .... A patient should be denied the
opportunity to weigh the risks only where it is evident he cannot
evaluate the data, as for example, where there is an emergency or
the patient is a child or incompetent."
Given the inevitably fatal nature of AIDS and its 20% to 30% probability of
development from exposure to HIV," the exposure risk via transfusion
could reasonably be found material even though its statistical probability is
quite small. And, as the above quote unequivocally indicates, this is a deci-
sion for the patient. Nor is it likely that the transfusion risk could be found to
be generally known, obviating a duty to disclose, given, for example, New
York Times headlines which read "Blood Supply Called Free of AIDS."85
In both informed consent and conventional malpractice considerations,
the availability of alternative, significantly safer procedures would weigh
heavily in considerations of liability. Malpractice is usually determined to be
a failure of a professional to exercise the degree of care and skill ordinarily
possessed and employed by members of the profession in good standing. If
schools of thought differ, the doctor is generally entitled to be judged accor-
'Scott v. Bradford, 606 P.2d 544 (Sup. Ct. Okla. 1979).
"Cobbs v. Grant, 8 Cal. 3d 229, 502 P.2d 1, 104 Cal. Rptr. 505 (1972).
"See supra notes 1-5 and accompanying text.
"Altman, Blood Supply Called "Free of AIDS", N.Y. Times, Aug. 1, 1985, at 1, col. 1.
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ding to the standards of the school of thought to which he belongs, assum-
ing it is shared by some respectable minority of the profession.6
It must be emphasized, however, that the general standards of a profes-
sion or school of thought may be rejected by the court as insufficient: "[Iln
most cases reasonable prudence is in fact common prudence; but strictly it is
never its measure; a whole calling may have unduly lagged in the adoption
of new and available devices. It may never set its own tests, however persua-
sive be its usage. Courts must in the end say what is required.""
This caveat is key to many blood transfusion situations because of the
availability of other, safer methods of supplying blood for any non-
emergency surgery. Autologous blood transfusions, wherein blood is col-
lected from a patient for retransfusion at a later time, is one such method.
Autologous transfusions eliminate the risk of infection entirely, are en-
dorsed by the American Association of Blood Banks as the safest type of
transfusion, and in some cases may be less expensive than homologous (i.e.,
conventional, third-party donor) transfusions. In addition, any patient
whose status is stable enough to allow elective surgery can generally donate
several units of blood for autologous transfusions in the weeks leading up to
surgery, including, if necessary, pregnant women or people with cardiovas-
cular disease.8 A consortium of blood supply organizations have strongly
endorsed more frequent use of autologous blood transfusions, especially in
elective surgery situations, in light of the AIDS epidemic? ° This is recom-
mended notwithstanding the fact that "local blood center protocols for auto-
logous donation may be unwieldy and inconvenient for surgeons, patients,
the transfusion service, and the blood center."91
Surgeons underutilizing autologous transfusions, though following ac-
cepted surgical practices, may nevertheless be exposing themselves to liabil-
ity unnecessarily. (It should be emphasized that directed donations - in
which family or friends donate blood for use during an operation on a partic-
16See, e.g., Creasy v. Hogan, 292 Or. 154, 637 P.2d 114 (1981); Hersh v. Hendley, 626 S.W.2d
151 (Tex. Ct. App. 1981); Roberts v. Tardif, 417 A.2d 444 (Me. 1980); Joy v. Chau, 177 Ind. App.
29, 377 N.E.2d 670 (1978); Chumbler v. McClure, 505 F.2d 489 (6th Cir. 1974).
1-Ielling v. Carey, 83 Wn. 2d 514, 519 P.2d 981 (1974) (quoting The T.J. Hooper, 60 F.2d 737,
740 (2d Cir. 1932) (italics in original).
ACouncil on Scientific Affairs, supra note 21.
89d.
'Joint Statement on Acquired Immune Deficiency Syndrome Related to Transfusion, 23 TRANSFuSION
87, 88 (1983) [hereinafter Joint Statement].
9Underutilization of Autologous Blood Donation Among Eligible Elective Surgical Patients, 152 AM
J. oF SURGERY 483, 485 (1986).
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ular individual - are almost uniformly condemned as being no safer than
blood collected routinely from volunteer donors.3 Failure to suggest di-
rected- donations would therefore not be equivalent to failure to describe
autologous procedures.)
The informed consent doctrine duty to warn is separate from the Com-
ment k requirement that products are "accompanied by proper directions
and warning." It is rare that the seller of a unit of blood interacts with the
patient in any way, or that the patient has effective access to the warnings of
the blood product itself. Blood products may have warnings affixed to them
regarding the risk of hepatitis," but do not yet have warnings regarding the
possibility of contracting AIDS.
Some pharmaceutical cases have held that even where a warning is made
to the physician, such as might be written on a blood bag, if the manufac-
turer had reason to know that the drug will reach the recipient without an
explanation of the risks attending the use of the drug, the manufacturer
must take reasonable steps to warn the recipient directly. 9 Some of the fac-
tual questions related to the manufacturers' duty to warn and the adequacy
of those warnings have been examined, indicating that both actual and con-
structive knowledge of the manufacturer may be weighed. 9
These issues are made somewhat more murky by the possibility of six
months passing before it becomes technologically feasible in a clinical envi-
ronment to detect whether or not exposure to HIV has caused an infection.
Outside the clinical environment, it may take eight years for symptoms to
manifest themselves, if they are going to at all.9 Because of these time lags,
any casual affair - homosexual, bisexual, or heterosexual - could be an av-
enue of HIV exposure even if it took place several years before, 97 as could any
experimentation with intravenous drug use involving shared needles.
In that intravenous drug use, homosexuality promiscuity, and use of
prostitutes are frequently viewed as morally questionable - and are in
92Menitove & Bove, Potential Liability for Transfusion-Associated AIDS, 255 J.A.M.A. 195, 197
(1986).
93See, e.g., Whitehurst v. American Nat'l. Red. Cross, 1 Ariz. App. 326, 402 P.2d 584 (1965).
"See, e.g., Reyes v. Wyeth Laboratories, 498 F.2d 1264 (5th Cir. 1974).
9
'See, e.g., Dalke v. Upjohn Co., 555 F.2d 245 (9th Cir. 1977); McEwen v. Ortho Pharmaceuti-
cal, 270 Or. 375, 528 P.2d 522 (1974) (generally maintaining that actual knowledge may be mea-
sured by adverse reaction reports, research results, etc., and that constructive knowledge may
be inferred from scientific literature and other technical and non-technical sources).
%Heil & Hemley, supra note 20.
'"When a person has sex, they're not just having it with that partner. They're having it with
everybody that partner has had it with for the past 10 years." Health and Human Services Secre-
tary Otis Bowen, quoted in Overhead, NwswEFac, Feb. 9, 1987, at 21.
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many cases illegal - questions of character, reputation, and conduct could
play a large role in the litigation of AIDS/blood transfusion cases, but for
their civil (rather than criminal) nature.
Just as a woman alleging rape by a given defendant may be met by that
defendant's attempts to introduce evidence of her character to support a de-
fense of consent,6 a plaintiff alleging that he had contracted AIDS through
transfusion of tainted blood could expect to be met by allegations of prior
practices known to be high risk behaviors if any such evidence were availa-
ble. Although evidence of a pertinent trait of character may be admissible in
the form of a criminally accused or a victim "for the purpose of proving he
acted in conformity therewith on a particular occasion,"" it has been held
that such evidence may not be introduced in civil cases.1" The effect of these
rules is somewhat tempered by allowing the credibility or character for
truthfulness of witnesses to be attacked.'0
In civil cases, however, the physical condition of a party may be examined
if there is "good cause" shown, and his condition is "in controversy. "'0 Pre-
sumably, all blood tested positively for HIV antibodies is disposed of.
Donor(s) alleged to be the source of contaminated transfusion would require
additional testing to determine whether or not HIV presence has been mani-
fested subsequent to donation to establish a prima facie case. (Clearly, HIV
presence in a donor would be by no means conclusive, but it would be a sine
qua non of the actual cause element of a tort claim.) Such presence is the es-
sence of the plaintiff's claim and would probably pass both the "good cause"
and "in controversy" tests, and such tests would probably be allowed in the
event the donor was made a party. 03
The records of blood testing are often kept confidential, however, be-
cause of a physician/patient privilege, or to maintain donor anonymity and
minimize the risk of employer or insurance discrimination.10' Under certain
circumstances, there may be modifications to discovery orders which can
provide the factual information sought without violating privacy of parties
"FED. R. EVID. 404(a)(1), 405.
"Statutes which disallow evidence of prior sexual history may conceivably be distinguished
by legislative intent.
1'0See, e.g., Nakasian v. Incontrade, Inc., 78 F.R.D. 229 (S.D.N.Y. 1978).
'
01FE. R. EviD. 607, 608.
"'FED. R. EviD. 35(a).
""See generally Schiagenhauf v. Holder, 379 U.S. 104 (1964).
104Morganthau, supra note 15, at 39.
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wishing to remain anonymous."' Where this question has been explicitly
raised, however, the court has chosen to forego allowing discovery of donor
names in deference to the privacy interests involved and the public interest
in maintaining the voluntary blood donor system. '
In Rasmussen v. South Florida Blood Services, "' the plaintiff sought damages
for aggravation of injuries received in an automobile accident. In the course
of treatment, the plaintiff was transfused with 51 units of blood collected
from volunteer donors. ' The District Court of Appeals of Florida held that
for purposes of assessing a discovery request for those donors' names and
addresses, many factors had to be balanced."10 In assessing the relative inter-
ests of the parties, the court seemed to find the defendant's checking its list
of donors against the county health service list of AIDS victims sufficient to
make "the probative value of the evidence which might be
discovered... questionable."" 0
In that nearly a decade could pass before an I-IV-infected donor might
manifest symptoms, this view may unfairly favor the blood supplier and un-
duly prejudice the plaintiff's case. This fact was characterized by the dissent
as "overkill of the worst kind."'
Notwithstanding the dissent, the District Court of Appeals certified the
following question:
Do the privacy interests of volunteer blood donors and a blood ser-
vice's and society's interest in maintaining a strong volunteer blood
donation system outweigh a plaintiff's interest in discovering the
names and addresses of the blood donors in the hope that further
discovery will provide some evidence that he contracted AIDS from
transfusions necessitated by injuries which are the subject of his
suit?
2
The Supreme Court of Florida has answered this question in the affirma-
tive. 113
"'See, e.g., FED. R. CIv. P. 26(c)(2).
"1South Ha. Blood Serv., Inc., v. Rasmussen, 467 So. 2d 798 (Fla. Dist. Ct. App. 1985).





'id. at 805, n.13.
luRasmussen v. South Fla. Blood Serv., Inc., No. 67081 (Sup. Ct. Fla. Jan. 5, 1987).
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Rasmussen not only prevents the discovery of information which could
help establish cause-in-fact in possibly showing that one or more donors
was an HIV carrier (which is, again, inconclusive, in that the donor could
have been exposed to HIV subsequent to donation), it also prevents a pa-
tient from constructing other aspects of a negligence claim.
For example, it has been held that although statutorily immune from strict
liability, blood suppliers must nonetheless exercise the standard of care ex-
pected of them."4 Those making tort claims against them for alleged blood-
product defects bear the burden of showing that the manufacturer was ei-
ther negligently or intentionally at fault."' Blood suppliers have been found
negligent for laxness in donor screening. In Hoder v. Sayet," 6 for example,
potential donors were not asked pertinent questions about their medical his-
tory which would have excluded them from donating. It has also been sug-
gested that collecting blood from high risk areas (such as poor neighbor-
hoods) may be negligent."7 In the case of AIDS, it could be found to be
negligence to collect blood from prison inmates, given that 50% of inmate
deaths are from AIDS." 8
Even the exercise of careful testing might not ameliorate collection from
such a population, given the exposure/detection gap in current tests. With-
out access to the donors via discovery (which may certainly be controlled to
prevent disclosure in any public forum or record*9), no opportunity arises to
question them on the blood donation routine they were actually exposed to,
effectively cutting off much of the development of evidence necessary to a
negligence claim.
V. Proposed Legislative Measures
The alarming growth of AIDS and its crossover from high risk groups into
the general population promise to multiply the cases alleging transfusion-
"
4Hoder v. Sayet, 196 So. 2d 205 (Fla.Dist.Ct.App. 1967).
"SHyland Therapeutics v. Superior Court, 175 Cal. App. 3d 509, 220 Cal. Rptr. 590 (1985),
rev'g Gallagher v. Cutter Laboratories, No. 548947 (Santa Clara Super Ct. filed May 11, 198), afg
Fogo v. Cutter Laboratories, 68 Cal. App. 3d 744, 137 Cal. Rptr. 417 (1977) (barring strict liability
claims against blood products manufacturers).
"
6Hoder, 196 So. 2d at 205.
"'See, e.g., Hutchins v. Blood Serv. of Montana, 161 Mont. 359, 506 P.2d 449 (1973).
11Doe v. Coughlin, 125 A.D.2d 783, 509 N.Y.S.2d 209, 212 (1986).
"'See generally, South Fla. Blood Serv., Inc. v. Rasmussen, 467 So.2d 798 (Fla.Dist.Ct.App.
1985).
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contracted AIDS. While some of these cases may be motivated by a desire to
demonstrate that a particular case of AIDS was not a product of activities
some find normatively questionable, hundreds of cases per year will be fully
justified based on current estimates of HIV contamination in the blood sup-
ply.'" Because of the potential for very long incubation periods, the problem
may persist for decades. Already AIDS/transfusion actions have been dis-
missed as time-barred by the relevant statute of limitations. 2 1 The interests
of fairness, judicial expediency, and safety of the blood supply suggest that
legislative measures are in order to minimize or ameliorate problems asso-
ciated with current practices.
Codification of more highly discriminating donor screening procedures
may go far toward standardizing criteria for both collecting agencies and the
courts. Blood dotting factor manufacturers have added cervical lymph node
palpation for lymphadenopathy, a potential precursor to AIDS, to their do-
nor screening routine.' FDA donor-deferral recommendations have been
reworded to screen out any man that has had sex even once with another
man since 1977.'" Case law has upheld one state's requirement that inter-
viewers be "ingenious" in their prescreening questions, to most effectively
minimize high risk donors. 1 However, joint statements from The American
Association of Blood Banks and Council of Community Blood Centers have
indicated that "[d]irect or indirect questions regarding a donor's sexual pref-
erence are inappropriate."1
It is possible to provide privacy of interviews and examinations, as it is
possible to ensure confidentiality of results. The American Red Cross al-
ready has an operational "confidential unit exclusion" system which allows
donors to confidentially self-defer their blood if they have somehow been
pressured to donate, though there is some reason their blood ought not be
transfused.'" Voluntary self-deferral alone, it must be emphasized, is inade-
quate to protect the blood supply. One study showed that a request for vol-
untary self-exclusion decreased at-risk group donations by no more than
"'See supra notes 38, 39, 56, 73, and accompanying text.
"'Savino v. Nassau Hosp., No. 2600E (N.Y.App. Div. Feb. 2, 1987).
ln Guidelines for Recall of Blood from AIDS Donors? FDA Says No, MEDICAL WORLD NEws, Aug.
22, 1983, at 24.
'
0 Center for Drugs and Biologics, FDA & AIDS Bureau, CDC, Revised Definition of Persons
Who Sould Refrain from Donating Blood and Plasma 254 J.A.M.A. 1886 (1985).
1"'Joint Statement, supra note 90.
15Hoder v. Sayet, 196 So. 2d 205 (Fla. Dist. Ct. App. 1967).
"1Gabe, supra note 71, at 7-B, col. 5.
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50%.12' Donations were even received from homosexual men diagnosed
with ARC, all of whom had read a request for voluntary self-exclusion. I'
To ensure greater safety of the blood supply, then, detailed questioning
to determine whether or not an individual may be in a high-risk group and at
least a cursory physical examination should be performed. Each of these
may already be the routine practice at blood banks, but codification of these
procedures would convert a cause of action for post-transfusion AIDS to one
of negligence per se, which is free of many of the problems to which other
theories are prone. Some certification by the blood collecting entity that the
appropriate questions were asked and the examination performed, initialed
by the donor, could attend these more involved screening procedures to fa-
cilitate judicial scrutiny. With these codified, standardized procedures, judi-
cial scrutiny would be consistent from case to case, a comparison of actions
to statutory requirements rather than against conflicting testimony of expert
witnesses.
Autologous blood transfusions should be encouraged wherever possible
- perhaps statutorily required for all elective surgery. This would ensure
that patients are not exposed to any diseases they do not already have, and
would effectively eliminate the possibility of such suits as have been dis-
cussed in this Note. While establishing protocols for autologous blood sup-
ply may involve an initial capital outlay, reduced testing and typing require-
ments and presumably lower liability insurance may serve to offset some of
these costs.
Where homologous blood is used, the ordering physician or surgeon
should be required to warn the patient of the HIV-contamination risk. This
warning should be accompanied by a written consent form, similar to, but
separate from the consent form originally required for surgery. This would
ensure that patients are not exposed to any diseases they do not already
have, and would effectively eliminate the possibility of such suits as have
been discussed in this Note. While establishing protocols for autologous
blood supply may involve an initial capital outlay, reduced testing and typ-
ing requirements and presumably lower liability insurance may serve to off-
set some of these costs.
This would also serve to meet the requirements of the informed consent
doctrine, and give the patient explicit warning of the remote possibility of
lvWykoff & Halsey, The Effectiveness of Voluntary Self-Exclusion on Blood Donation Practices of
Individuals at High Risk for AIDS, 256 J.A.M.A. 1293 (1986).
1281d.
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MV infection. Blood and blood products themselves should be accompa-
nied by warnings of the risk of HIV presence, both to meet the Comment k
warning requirement and to remind physicians of their own duty to warn.
In order to counter the possible reduction in volunteer blood donations
because of misunderstanding of some aspect of these decisions (e.g., that
donation rather than transfusion may be an AIDS vector), an incentive to
donate in the form of a tax deduction or credit is also recommended. This
could be so structured to encourage donations from population segments
that do not share the possible health problems often associated with paid
blood donors.'- In that each AIDS victim requires approximately $140,000
for his care,' 30 the encouragement of donations from non-high-risk popula-
tions serves a serious, legitimate state health interest.
VI. Conclusion
The details of blood collection and current methods of ensuring the safety
of the blood supply have been described. The common causes of action for
post-transfusion illness were examined, with an emphasis on how AIDS has
been or might be treated by the courts. These common theories of recovery
- breach of warranty, strict liability in tort, res ipsa loquitor, negligence -
present procedural, proof, or policy complexities that do not lend them-
selves to consistent, just adjudication. To ameliorate problems associated
with these theories, legislation is suggested to set uniform, high standards
for blood donor screening, to promote safer alternatives to homologous
transfusions and provide adequate warnings where alternatives are unavail-
able, and to provide tax incentives to promote volunteer blood donations.
These measures collectively serve the interests of fairness, judicial effi-
ciency, and the preservation of an adequate and safe blood supply.
Lawrence K. English
'2Gabe, supra note 71.
'051 Fed. Reg. 20,553 (1986). Costs vary greatly from city to city, with the type of care, and
with the longevity of the victim.
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